Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Relapsed/Refractory B-cell NHL
NCT03009344Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in B-cell non-Hodgkin lymphoma, sponsored by Eisai Co., Ltd. Primary endpoint: Number of Participants With Dose-limiting Toxicities. Started Jan 2017; status: completed.
02
Drugs
tazemetostat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03009344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009344.